Cryofocus Medtech (Shanghai) Future Growth
Future criteria checks 2/6
Cryofocus Medtech (Shanghai) is forecast to grow earnings and revenue by 66.9% and 48.8% per annum respectively. EPS is expected to grow by 67.9% per annum. Return on equity is forecast to be -20.2% in 3 years.
Key information
66.9%
Earnings growth rate
67.9%
EPS growth rate
Medical Equipment earnings growth | 34.1% |
Revenue growth rate | 48.8% |
Future return on equity | -20.2% |
Analyst coverage | Low |
Last updated | 25 Jul 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 591 | N/A | 60 | N/A | 1 |
12/31/2025 | 343 | -15 | -28 | 0 | 1 |
12/31/2024 | 162 | -72 | -87 | -64 | 1 |
12/31/2023 | 41 | -97 | -111 | -96 | N/A |
9/30/2023 | 38 | -105 | -116 | -106 | N/A |
6/30/2023 | 36 | -113 | -122 | -115 | N/A |
3/31/2023 | 31 | -113 | -113 | -106 | N/A |
12/31/2022 | 27 | -112 | -104 | -97 | N/A |
12/31/2021 | 22 | -102 | -75 | -62 | N/A |
12/31/2020 | 9 | -137 | -36 | -34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6922 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6922 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6922 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6922's revenue (48.8% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 6922's revenue (48.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6922 is forecast to be unprofitable in 3 years.